Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Adjuvant Anlotinib in Stage IA NSCLC at High Risk of Recurrence
ChiCTR2000037398Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing Anlotinib adjuvant therapy with Observation (2 arms). Primary endpoint: overall survival. Started Sep 2020; status: recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000037398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037398.